Claudin-3 - a new intestinal integrity marker in patients with psoriasis: association with disease severity.

摘要: BACKGROUND Gut dysbiosis and increased intestinal permeability play a significant role in the pathogenesis of psoriasis its comorbidities. Claudin-3 is key component tight junctions, which may serve as marker gut barrier integrity. OBJECTIVES The aim study was to investigate circulating plasma claudin-3 patients with evaluate clinical metabolic factors, determine concentration. METHODS This cross-sectional included 60 (39 men 21 women, mean age: 45.6 ± 12.1 years) 30 healthy controls (18 12 46.3 ± 15.5 years) age, sex body mass index-matched. Plasma concentration measured using an enzyme-linked immunosorbent assay. RESULTS significantly higher comparison control [median (interquartile range), 50.7 ng/mL (47.3-54.2) vs. 43.3 ng/mL (42.3-44.2), P < 0.001]. Patients who achieved ΔPASI90 response after 16 weeks treatment showed tendency decrease Positive correlations between PASI score (r = 0.828; P < 0.001) well neutrophil-to-lymphocyte ratio (r = 0.847; were found. A multivariable linear regression analysis confirmed association (P < 0.001), (P < 0.01) active smoking (P < 0.05). CONCLUSION Claudin-3, biomarker for permeability, correlates disease severity smoking. Further investigations are needed whether reinforcing be new therapeutic target psoriasis.